Category - Developments

Developments

BeyondSpring receives U.S. composition of matter patent for Plinabulin

BeyondSpring (NASDAQ:BYSI) received a new composition of matter patent for its lead asset, Plinabulin, from the U.S. Patent and Trademark Office. As a polymorph, Pinabulin can be converted into multiple crystalline...

December 21, 2018

Developments

Canopy Rivers affiliate gains traction in New Jersey medical cannabis market

Canopy Rivers (TSXV:RIV) announced that NETA NJ LLC, a company controlled by its portfolio company, TerrAscend (CSE:TER; OTCQX:TRSSF), has been selected by the State of New Jersey Department of Health to apply for final...

December 19, 2018

Developments

IntelGenx in pact with Gensco Pharma to market RIZAPORT in U.S.

IntelGenx (TSX-V:IGX; OTCQX:IGXT) signed a definitive licensing, development and supply agreement with Gensco Pharma, a specialty pharmaceutical company, for the exclusive commercialization of RIZAPORT in the U.S. “With...

December 12, 2018

Developments

LexaGene completes development of canine UTI syndromic panel

LexaGene Holdings (OTCQB:LXXGF; TSX-V:LXG) has completed development of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common...

December 12, 2018

Developments

Research finds cancer detection in 10-minute blood test

Researchers in Australia have developed a simple blood test they claim can diagnose cancer in 10 minutes by identifying a unique DNA signature present in all types of the disease. While the test has yet to be studied in...

December 6, 2018

Developments

Canopy Growth acquires Storz & Bickel for up to €145-million

Canopy Growth (TSX:WEED; NYSE:CGC) finalized an all-cash transaction to acquire Storz & Bickel GmbH for up to approximately €145-million. Storz & Bickel is widely recognized as the global leader in vaporizer...

December 6, 2018

Developments

BeyondSpring posts positive interim analysis of Plinabulin for chemotherapy-induced neutropenia

BeyondSpring (NASDAQ:BYSI) announced that the Phase 3 portion of its Study 105 evaluating its lead asset, Plinabulin, in patients treated with docetaxel chemotherapy has met its primary endpoint of non-inferiority...

December 6, 2018

Developments

Scientus Pharma receives U.S. patent for cannabis extraction technology

Closely-held Scientus Pharma, through its HydRx Farms unit, received a U.S. patent that provides intellectual property protection for its decarboxylation method for extraction and activation of active pharmaceutical...

December 5, 2018

Developments

BeyondSpring presents positive Plinabulin CIN data at ASH

BeyondSpring (NASDAQ:BYSI) reported new data from its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) annual meeting. Plinabulin is...

December 4, 2018

Developments

Canopy Growth in equity investment, supply deal, strategic partnership with 48North

Canopy Growth (TSX:WEED; NYSE: CGC) inked an investment financing, and partnership and a supply agreement with 48North Cannabis (TSXV:NRTH). Under the supply accord, 48North would supply Canopy with dried cannabis...

December 3, 2018

Category - Developments

Subscribe